Expression of Acetylcholinesterase in Alzheimer’s Disease Brain: Role in Neuritic Dystrophy and Synaptic Scaling

  • David H. Small
  • Steven Petratos
  • Sharon Unabia
  • Danuta Maksel
Conference paper
Part of the Advances in Behavioral Biology book series (ABBI, volume 57)


Mild Cognitive Impairment Amyloid Plaque Nicotinic Receptor Cholinergic Neuron Basal Forebrain 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Small DH, Mok SS, Bornstein JC. Alzheimer's disease and Aβ toxicity: from top to bottom. Nat Rev Neurosci 2001;2:595–598.PubMedCrossRefGoogle Scholar
  2. Probst A, Langui D, Ulrich J. Alzheimer's disease: a description of the structural lesions. Brain Pathol 1991;1:229–239.PubMedGoogle Scholar
  3. Larner AJ. The cortical neuritic dystrophy of Alzheimer's disease: nature, significance, and possible pathogenesis, Dementia 1995;6:218–224.Google Scholar
  4. Knowles RB, Wyart C,. Buldyrev SV, et al. Plaque-induced neurite abnormalities: implications for disruption of neural networks in Alzheimer's disease. Proc Natl Acad Sci U S A 1999;96:5274–5279.PubMedCrossRefGoogle Scholar
  5. Mesulam MM, Geula C. Shifting patterns of cortical cholinesterases in Alzheimer's disease: implications for treatment, diagnosis, and pathogenesis. Adv Neurol 1990;51:235–240.PubMedGoogle Scholar
  6. Carson KA, Geula C, Mesulam MM. Electron microscopic localization of cholinesterase activity in Alzheimer brain tissue. Brain Res 1991;540:204–208.PubMedCrossRefGoogle Scholar
  7. Wright CI, Geula C, Mesulam MM. Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability. Ann Neurol 1993;34:373–384.PubMedCrossRefGoogle Scholar
  8. Geula C, Greenberg BD, Mesulam MM. Cholinesterase activity in the plaques, tangles and angiopathy of Alzheimer's disease does not emanate from amyloid. Brain Res 1994;644:327–330.PubMedCrossRefGoogle Scholar
  9. Small DH. Acetcholinesterase inhibitors for the treatment of dementia in Alzheimer's disease: do we need new inhibitors? Exp Opin Drug Dev 2005;10:817–825.CrossRefGoogle Scholar
  10. Massoulie J, Sussman J, Bon S, Silman I. Structure and functions of acetylcholinesterase and butyrylcholinesterase. Prog Brain Res 1993;98:139–146.PubMedGoogle Scholar
  11. Sberna G, Saez-Valero J, Beyreuther K, et al. The amyloid β-protein of Alzheimer's disease increases acetylcholinesterase expression by increasing intracellular calcium in embryonal carcinoma P19 cells. J. Neurochem. 1997;69:1177–1184.PubMedGoogle Scholar
  12. Saez-Valero J, Fodero LR, White AR, et al. Acetylcholinesterase is increased in mouse neuronal and astrocyte cultures after treatment with β-amyloid peptides. Brain Res 2003;965:283–286.PubMedCrossRefGoogle Scholar
  13. Sberna G, Saez-Valero J, Li QX, et al. Acetylcholinesterase is increased in the brains of transgenic mice expressing the C-terminal fragment (CT100) of the β-amyloid protein precursor of Alzheimer's disease. J Neurochem 1998;71:723–731.PubMedCrossRefGoogle Scholar
  14. Saez-Valero J, Sberna G, McLean CA, Small DH. Molecular isoform distribution and glycosylation of acetylcholinesterase are altered in brain and cerebrospinal fluid of patients with Alzheimer's disease. J Neurochem 1999;72:1600–1608.PubMedCrossRefGoogle Scholar
  15. Saez-Valero J, Sberna G, McLean CA, et al. Glycosylation of acetylcholinesterase as diagnostic marker for Alzheimer's disease. Lancet 1997;350:929.PubMedCrossRefGoogle Scholar
  16. Saez-Valero J, Barquero MS, Marcos A, et al. Altered glycosylation of acetylcholinesterase in lumbar cerebrospinal fluid of patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2000;69:664–667.PubMedCrossRefGoogle Scholar
  17. Saez-Valero J, Fodero LR, Sjogren M, et al. Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease. J Neurosci Res 2003;72:520–526.PubMedCrossRefGoogle Scholar
  18. Fodero LR, Saez-Valero J, McLean CA, et al. Altered glycosylation of acetylcholinesterase in APP (SW) Tg2576 transgenic mice occurs prior to amyloid plaque deposition. J Neurochem 2002;81:441–448.PubMedCrossRefGoogle Scholar
  19. Dani JA. Overview of nicotinic receptors and their roles in the central nervous system. Biol Psychiatry 2001;49:166–174.PubMedCrossRefGoogle Scholar
  20. Albuquerque EX, Pereira EF, Castro NG, et al. Nicotinic receptor function in the mammalian central nervous system. Ann N Y Acad Sci 1995;757:48–72.PubMedCrossRefGoogle Scholar
  21. Mann EO, Greenfield SA. Novel modulatory mechanisms revealed by the sustained application of nicotine in the guinea-pig hippocampus in vitro. J Physiol 2003;551:539–550.PubMedCrossRefGoogle Scholar
  22. Wang HY, Lee DH, D'Andrea MR, et al. β-Amyloid(1-42) binds to α7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem 2000;275:5626–5632.PubMedCrossRefGoogle Scholar
  23. Pettit DL, Shao Z, Yakel, JL. β-Amyloid(1-42) peptide directly modulates nicotinic receptors in the rat hippocampal slice. J Neurosci 2001;21:RC120.PubMedGoogle Scholar
  24. Tozaki H, Matsumoto A, Kanno T, et al. The inhibitory and facilitatory actions of amyloid-β peptides on nicotinic ACh receptors and AMPA receptors. Biochem Biophys Res Commun 2002;294:42–45.PubMedCrossRefGoogle Scholar
  25. Liu Q, Kawai H, Berg DK. β -Amyloid peptide blocks the response of α7-containing nicotinic receptors on hippocampal neurons. Proc Natl Acad Sci USA 2001;98:4734–4739.PubMedCrossRefGoogle Scholar
  26. Dineley KT, Westerman M, Bui D, et al. β-Amyloid activates the mitogen-activated protein kinase cascade via hippocampal α7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci 2001;21:4125–4133.PubMedGoogle Scholar
  27. Dineley KT, Bell KA, Bui D, Sweatt JD. β-Amyloid peptide activates α7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Biol Chem 2002;277:25056–25061.PubMedCrossRefGoogle Scholar
  28. Yu WF, Guan ZZ, Bogdanovic N, Nordberg A. High selective expression of α7 nicotinic receptors on astrocytes in the brains of patients with sporadic Alzheimer's disease and patients carrying Swedish APP 670/671 mutation: a possible association with neuritic plaques. Exp Neurol 2005;192:215–225.PubMedCrossRefGoogle Scholar
  29. Xiu J, Nordberg A, Zhang JT, Guan ZZ. Expression of nicotinic receptors on primary cultures of rat astrocytes and up-regulation of the α7, α4 and β2 subunits in response to nanomolar concentrations of the β-amyloid peptide(1-42). Neurochem Int 2005;47:281–290.PubMedCrossRefGoogle Scholar
  30. Fodero LR, Mok SS, Losic D, et al. α7-nicotinic acetylcholine receptors mediate an Aβ(1-42)-induced increase in the level of acetylcholinesterase in primary cortical neurones. J Neurochem 2004;88:1186–1193.PubMedCrossRefGoogle Scholar
  31. Struble RG, Cork LC, Whitehouse PJ, Price DL. Cholinergic innervation in neuritic plaques. Science 1982;216:413–415.PubMedCrossRefGoogle Scholar
  32. Kitt CA, Price DL, Struble RG, et al. Evidence for cholinergic neurites in senile plaques. Science 1984;226:1443–1445.PubMedCrossRefGoogle Scholar
  33. Masliah E, Alford M, Adame A, et al. Aβ1-42 promotes cholinergic sprouting in patients with AD and Lewy body variant of AD. Neurology 2003;61:206–211.PubMedGoogle Scholar
  34. Hernandez D, Sugaya K, Qu T, et al. Survival and plasticity of basal forebrain cholinergic systems in mice transgenic for presenilin-1 and amyloid precursor protein mutant genes. Neuroreport 2001;12:1377–1384.PubMedCrossRefGoogle Scholar
  35. Hu L, Wong TP, Cote SL, et al. The impact of Aβ-plaques on cortical cholinergic and non-cholinergic presynaptic boutons in alzheimer's disease-like transgenic mice. Neuroscience 2003;121:421–432.PubMedCrossRefGoogle Scholar
  36. DeKosky ST, Ikonomovic MD, Styren SD, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 2002;51:145–155.PubMedCrossRefGoogle Scholar
  37. Ikonomovic MD, Mufson EF, Wuu J, et al. Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: correlation with Alzheimer's neuropathology. J Alzheimers Dis 2003;5:39–48.PubMedGoogle Scholar
  38. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004;363:2105–2115.PubMedCrossRefGoogle Scholar
  39. Small DH. Do acetylcholinesterase inhibitors boost synaptic scaling in Alzheimer's disease? Trends Neurosci 2004;27:245–249.PubMedCrossRefGoogle Scholar
  40. Turrigiano GG. Homeostatic plasticity in neuronal networks: the more things change, the more they stay the same. Trends Neurosci 1999;22:221–227.PubMedCrossRefGoogle Scholar
  41. Davis GW, Goodman CS. Synapse-specific control of synaptic efficacy at the terminals of a single neuron. Nature 1998;392:82–86.PubMedCrossRefGoogle Scholar
  42. Ruppin E, Reggia JA. A neural model of memory impairment in diffuse cerebral atrophy. Br J Psychiatry 1995;166:19–28.PubMedCrossRefGoogle Scholar
  43. Storey E, Kinsella GJ, Slavin MJ. The neuropsychological diagnosis of Alzheimer's disease. J Alzheimers Dis 2001;3:261–285.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • David H. Small
    • 1
  • Steven Petratos
  • Sharon Unabia
  • Danuta Maksel
  1. 1.Department of Biochemistry and Molecular BiologyMonash UniversityAustralia

Personalised recommendations